TIFFANY SPARGO: Open Payments
NPI 1073099198 · JONESBORO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,085 in 51 payments from 9 companies in 2025. Trend: 2023 $527 · 2024 $891 · 2025 $1,085
Food & beverage: $1,085
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $214 |
| Axsome Therapeutics, Inc. | 11 | $213 |
| Alkermes, Inc. | 6 | $159 |
| ABBVIE INC. | 9 | $156 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $147 |
| Lundbeck LLC | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Neurocrine BioSciences, Inc. | 2 | $41 |
| Janssen Pharmaceuticals, Inc | 2 | $35 |
Products named: Auvelity, REXULTI, ARISTADA, VRAYLAR, CAPLYTA, ABILIFY MAINTENA, TRINTELLIX, INGREZZA.
Industry payments across AR — which companies pay providers there.
